Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Joel Shertok, PhD, ex-Member of The Board, ex-Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

Affiliation with LPBI Group:

12/22/2019 – 5/4/2021

UPDATED on 11/9/2020

Selected Projects:

1. BOT-based Prospective System based on 12 Economic Segments 

Under exploration: New BOT Vendor

Opportunities Map in the Acquisition Arena

• Prepare one prototype for industry of your choice
• Scale up to 6 industries – get Aviva’s input in selection

2. IB communications

BIO

Dr. Joel Shertok

jshertok@processindconsultants.com  

302-562-9759

Dr. Joel Shertok is a senior level executive who has over 40 years of experience in the Chemical Process and Materials industries. His track record is characterized by: merger and acquisition experience, development of new product lines, creation of new business ventures, creation/motivation of new business teams, and international investigations of novel technologies.

Previously, Dr. Shertok has been a Research Fellow at Rochester Institute of Technology. He has held senior technical and managerial positions at Rochester Midland Corporation (formulated products and sanitizers, Graver Technologies (filtration and purification), Pall-Gelman Corporation (membrane filtration and water purification), Amoco Corporation (Carbon fiber composites and BioTechnology), and Union Carbide (specialty chemicals).

Dr. Shertok holds numerous patents in membrane technology, carbon purification, and in industrial food service cleaners. He is currently President of Process Industries Consultants, a chemical engineering consulting firm located in Newark, Delaware.

Curriculum Vitae

Responsibilities

Verticals:

(1) Chemical Industry

(2) Financials & Insurance: Health Care

(3) Biotech

(4) Private Equity

Business Development responsibilities @LPBI:

(1) All Documentation Artifacts expected by External Relation

(2) Client facing engagement with External relations: Information Syndication

(3) Development of a Bot-based Global Prospecting System for LPBI

3.1 applications on ALA’s 7,300

3.2 applications on JTS’s 1st degree connections on LinkedIn

(4) LPBI’s LEAD all efforts with IB

(5) LPBI’s LEAD for all Partnerships:

5.1 LPBI J-V (30%) with ABI-Lab (70%)

5.2 BurstIQ

5.3 Agreements with Wolfram Machine Learning Approach https://www.wolfram.com/featureset/machine-learning/ 

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

• 1,4,5, ABOVE

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

• 2,3,5, ABOVE

TNS #1: See 5.3, above – TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

TNS #2: See 5.2, above, Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: See 5.1, above Joint venture with Dr. Nir for Drug Discovery: 

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

• See 5.1, 5.2, 5.3, above

Publications with Leaders in Pharmaceutical Business Intelligence (LPBI) Group